PMID- 22968760
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20211021
IS  - 1559-1166 (Electronic)
IS  - 0895-8696 (Linking)
VI  - 50
IP  - 1
DP  - 2013 May
TI  - The effects of reboxetine treatment on depression-like behavior, brain 
      neurotrophins, and ERK expression in rats exposed to chronic mild stress.
PG  - 88-97
LID - 10.1007/s12031-012-9872-8 [doi]
AB  - Chronic mild stress (CMS) in rats is an established rodent depression model. 
      Antidepressants attenuate the depression-like symptoms and prevent the 
      biochemical changes caused by stress. In the present study, we examined the 
      effect of CMS and the selective norepinephrine reuptake inhibitor (NRI) 
      reboxetine (REB) treatment on behavioral parameters in rats and on hippocampal 
      and cortical neurotrophic factors. Male Sprague Dawley rats were exposed for 5 
      weeks to a variety of mild stressors. REB (5 mg/kg/i.p.) was daily injected to 
      half of the stressed and unstressed groups. Animal behavior following CMS was 
      tested using the Morris Water Maze (MWM) cognitive paradigm and by monitoring 
      sucrose intake and weight gain. After 5 weeks of CMS, stressed rats showed 
      decreased sucrose intake, and REB treatment normalized this decrease. CMS reduced 
      hippocampal brain-derived neurotrophic factor (BDNF) levels, and REB treatment 
      reversed this alteration and increased BDNF receptor (TrkB) levels. REB elevated 
      hippocampal extracellular signal-regulated kinase (ERK) phosphorylation of both 
      stressed and unstressed rats. In conclusion, our study shows that BDNF, its 
      receptor TrkB, and ERK participate in the neurobiological response to chronic 
      stress and in the molecular and cellular activities of REB in the hippocampus.
FAU - First, Maya
AU  - First M
AD  - Laboratory of Biological Psychiatry, Felsenstein Medical Research Center and 
      Sackler Faculty of Medicine, Tel-Aviv University, Petach Tikva 49100, Israel.
FAU - Gil-Ad, Irit
AU  - Gil-Ad I
FAU - Taler, Michal
AU  - Taler M
FAU - Tarasenko, Igor
AU  - Tarasenko I
FAU - Novak, Nurit
AU  - Novak N
FAU - Weizman, Abraham
AU  - Weizman A
LA  - eng
PT  - Journal Article
DEP - 20120912
PL  - United States
TA  - J Mol Neurosci
JT  - Journal of molecular neuroscience : MN
JID - 9002991
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Dietary Sucrose)
RN  - 0 (Morpholines)
RN  - 947S0YZ36I (Reboxetine)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Adrenergic Uptake Inhibitors/pharmacology/*therapeutic use
MH  - Animals
MH  - Antidepressive Agents/pharmacology/*therapeutic use
MH  - Brain/metabolism
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Depressive Disorder/*drug therapy/etiology/metabolism
MH  - Dietary Sucrose
MH  - Extracellular Signal-Regulated MAP Kinases/genetics/*metabolism
MH  - Food Preferences/drug effects
MH  - Gene Expression/drug effects
MH  - Male
MH  - Maze Learning/*drug effects
MH  - Morpholines/pharmacology/*therapeutic use
MH  - Phosphorylation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reboxetine
MH  - Receptor, trkB/genetics/metabolism
MH  - Stress, Psychological/*complications
MH  - Weight Gain/drug effects
EDAT- 2012/09/13 06:00
MHDA- 2013/10/18 06:00
CRDT- 2012/09/13 06:00
PHST- 2012/02/22 00:00 [received]
PHST- 2012/08/01 00:00 [accepted]
PHST- 2012/09/13 06:00 [entrez]
PHST- 2012/09/13 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - 10.1007/s12031-012-9872-8 [doi]
PST - ppublish
SO  - J Mol Neurosci. 2013 May;50(1):88-97. doi: 10.1007/s12031-012-9872-8. Epub 2012 
      Sep 12.